mat PROVIDER library
Telehealth for the Treatment of Serious Mental Illness and Substance Use Disorders - SAMHSA PEP21-06-02-001​
Section devoted to presentations and handouts at the 2021 ASAM Virtual Conference
ASAM New Definition of Addiction to Advance Greater Understanding of the Complex, Chronic Disease
CDC Addiction Medicine Primer
DHHS 42 CFR Part 8: 
Medication Assisted Treatment for Opioid Use Disorder
ASAM 2020 National Practice Guideline: FOR THE TREATMENT OF OPIOID USE DISORDER (Focused Update)
Discontinuing Methadone and Buprenorphine: A Review and Clinical Challenges.  (Journal of Addiction Medicine, Nov/Dec 2021).  This article also introduces the notion of 'Recovery Capital' in how to approach this discussion with patients desiring discontinuation of medication.
ASAM Six Dimensions for Ongoing Addiction Treatment
MEDICATIONS FOR OPIOID USE DISORDER:
For Healthcare and Addiction Professionals, Policymakers, Patients, and Families
SAMHSA Treatment Improvement Protocol (TIP) 63  -  published 2018, 
​2019 update
SUBLOCADE guidance for healthcare providers
​FDA WARNING:  dental problems have been reported with medicines containing buprenorphine that are dissolved in the mouth. The dental problems, including tooth decay, cavities, oral infections, and loss of teeth, can be serious and have been reported even in patients with no history of dental issues. 
CARING FOR WOMEN WITH OPIOID USE DISORDER
​(2020 HHS Guidance)​
CLINICAL GUIDANCE FOR TREATING PREGNANT AND PARENTING WOMEN WITH OPIOID USE DISORDER AND THEIR INFANTS : HHS Publication No. (SMA) 18-5054 
BUPRENORPHINE TREATMENT IN PREGNANCY
Perioperative Management with Buprenorphine for Patients engaged in MAT with Buprenorphine (arguing continuing at perhaps a reduced dose regimen). 2018 Review Article in Pain Medicine
More support for Perioperative Management of Buprenorphine (keeping it going at current dose or reduced daily regimen is slowly becoming the vogue in surgical care and standard of care. 2020 Review Article in Pain Medicine
Acute Pain Management in Patients with Opioid Use Disorder (joint presentation by Rebecca McCarthy, PharmD, & Walter Clark, MD at Inova Fairfax Hospital Internal Medicine Grands Rounds, 8/24/2021)
PCSS MAT Presentation on Benzodiazepines and Buprenorphine
Opioid Overdose Prevention Toolkit by SAMHSA
EMIT Drugs-of-Abuse Urine Assays Cross-Reactivity List
VIVITROL Protocol details for use in the clinical setting
Several references on interpreting Urine Drug Assays that detect CANNABINOIDS (all ain't just THC, so beware)
General Pain Management  Resources  (Pain-Outlet.Info website - by this same webmaster)
Marijuana & Medication Assisted Treatment for Opioid Use Disorder - "How can science inform agency policies?"  - by Ron Jackson, M.S.W., L.I.C.S.W., Affiliate Professor, School of Social Work, University of Washington -- Bottom line of presentation is as stated: "If you're concerned about your use of cannabis and would like to reduce or eliminate your use of it, we'd like to work with you to that goal."   -- This rather than the risk and harm of 'discharge', which leads to increased risk for mortality from opioid overdose.
BENZODIAZEPINE TAPER:   VA approach!   Excellent clinical guideline!
TRAUMA INFORMED CARE   (2014 SAMHSA guidance) prepared by SAMHSA's Trauma and Justice Strategic Initiative
TELEMEDICINE-Delivered Treatment for Opioid and Other Substance Use Disorders
​(VHA VISN 7 presentation supported by SAMHSA)